101 related articles for article (PubMed ID: 17526052)
1. Atemonate and Imuteran: novel Russian monoclonal antibody-based therapeutic agents.
Ivanov PK; Blokhin DY; Chmutin EF; Grinevich AS; Perlin DV; Sokolsky AS; Yakubovskaya RI; Baryshnikov AY
Biotechnol J; 2007 Jul; 2(7):863-70. PubMed ID: 17526052
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.
Baxevanis CN; Perez SA; Papamichail M
Cancer Immunol Immunother; 2009 Mar; 58(3):317-24. PubMed ID: 18704409
[TBL] [Abstract][Full Text] [Related]
3. [Monoclonal antibody-based design of antitumor drugs: prerequisites and progress].
Chmutin EF; Ivanov PK; Baryshnikov AIu
Vestn Ross Akad Med Nauk; 2004; (12):10-6. PubMed ID: 15678682
[TBL] [Abstract][Full Text] [Related]
4. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
5. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
6. Phage display derived human monoclonal antibodies isolated by binding to the surface of live primary breast cancer cells recognize GRP78.
Jakobsen CG; Rasmussen N; Laenkholm AV; Ditzel HJ
Cancer Res; 2007 Oct; 67(19):9507-17. PubMed ID: 17909061
[TBL] [Abstract][Full Text] [Related]
7. Antibody-cytotoxic agent conjugates for cancer therapy.
Chen J; Jaracz S; Zhao X; Chen S; Ojima I
Expert Opin Drug Deliv; 2005 Sep; 2(5):873-90. PubMed ID: 16296784
[TBL] [Abstract][Full Text] [Related]
8. Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer.
Frederick PJ; Straughn JM; Alvarez RD; Buchsbaum DJ
Gynecol Oncol; 2009 Jun; 113(3):384-90. PubMed ID: 19232697
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies to two epitopes of beta-human chorionic gonadotropin for the treatment of cancer.
Iversen PL; Mourich DV; Moulton HM
Curr Opin Mol Ther; 2003 Apr; 5(2):156-60. PubMed ID: 12772505
[TBL] [Abstract][Full Text] [Related]
10. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
11. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.
Khubchandani S; Czuczman MS; Hernandez-Ilizaliturri FJ
Curr Opin Investig Drugs; 2009 Jun; 10(6):579-87. PubMed ID: 19513947
[TBL] [Abstract][Full Text] [Related]
12. Recombinant polyclonal antibodies: the next generation of antibody therapeutics?
Haurum JS
Drug Discov Today; 2006 Jul; 11(13-14):655-60. PubMed ID: 16793535
[TBL] [Abstract][Full Text] [Related]
13. Technology insight: cytotoxic drug immunoconjugates for cancer therapy.
Ricart AD; Tolcher AW
Nat Clin Pract Oncol; 2007 Apr; 4(4):245-55. PubMed ID: 17392715
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
Greco FA; Bonomi P; Crawford J; Kelly K; Oh Y; Halpern W; Lo L; Gallant G; Klein J
Lung Cancer; 2008 Jul; 61(1):82-90. PubMed ID: 18255187
[TBL] [Abstract][Full Text] [Related]
15. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody therapy for prostate cancer.
Jakobovits A
Handb Exp Pharmacol; 2008; (181):237-56. PubMed ID: 18071949
[TBL] [Abstract][Full Text] [Related]
17. Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer.
Shen J; Zhu Z
Curr Opin Mol Ther; 2008 Jun; 10(3):273-84. PubMed ID: 18535935
[TBL] [Abstract][Full Text] [Related]
18. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity.
Boland WK; Bebb G
Expert Opin Biol Ther; 2009 Sep; 9(9):1199-206. PubMed ID: 19624281
[TBL] [Abstract][Full Text] [Related]
19. Technology evaluation: SGN-15, Seattle Genetics Inc.
Smith S
Curr Opin Mol Ther; 2001 Jun; 3(3):295-302. PubMed ID: 11497354
[TBL] [Abstract][Full Text] [Related]
20. Bispecific antibodies for dual-modality cancer therapy: killing two signaling cascades with one stone.
Marvin JS; Zhu Z
Curr Opin Drug Discov Devel; 2006 Mar; 9(2):184-93. PubMed ID: 16566289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
